Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients

Comprehensive Psychiatry

Volumn 71, Issue , 2016, Pages 71-76

  An, Feng Rong ^a   Yang, Rui ^a   Wang, Zhi Min ^a   Ungvari, Gabor S ^b,c   Ng, Chee H ^d   Chiu, Helen F K ^e   Wu, Ping Ping ^a   Jin, Xin ^a   Li, Lu ^f   Lok, Grace K I ^f,g   Xiang, Yu Tao ^f  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF NOTRE DAME   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f University of Macau   (Macao)

^g KIANG WU NURSING COLLEGE OF MACAU   (Macao)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CLOZAPINE; PROLACTIN; RISPERIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BREAST TENDERNESS; CHINESE; COHORT ANALYSIS; ERECTILE DYSFUNCTION; FEMALE; HUMAN; HYPERPROLACTINEMIA; ICD-10; LACTATION DISORDER; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MENSTRUATION DISORDER; MENTAL DISEASE; MENTAL PATIENT; MOOD DISORDER; QUALITY OF LIFE; SCHIZOPHRENIA; SHORT FORM 12; CASE CONTROL STUDY; CHEMICALLY INDUCED; CHINA; MENTAL DISORDERS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; YOUNG ADULT;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; CASE-CONTROL STUDIES; CHINA; CLOZAPINE; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; MENTAL DISORDERS; QUALITY OF LIFE; RISPERIDONE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; YOUNG ADULT;

EID: 84987940055     PISSN: 0010440X     EISSN: 15328384     Source Type: Journal    
DOI: 10.1016/j.comppsych.2016.08.009     Document Type: Article

References (25)

1. [1] Wang, ZM, Xiang, YT, An, FR, Correll, CU, Ungvari, GS, Wang, CY, et al. Frequency of hyperprolactinemia and its associations with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China. Perspect Psychiatr Care 50:4 (2014), 257–263.
2. [2] Ajmal, A, Joffe, H, Nachtigall, LB, Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics 55:1 (2014), 29–36.
3. [3] Montejo, AL, Majadas, S, Rico-Villademoros, F, Llorca, G, De La Gandara, J, Franco, M, et al. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sex Med 7:10 (2010), 3404–3413.
4. [4] Montejo, AL, Arango, C, Bernardo, M, Carrasco, JL, Crespo-Facorro, B, Cruz, JJ, et al. Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. Rev Psiquiatr Salud Ment 9:3 (2016), 158–173.
5. [5] Byerly, M, Suppes, T, Tran, QV, Baker, RA, Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 27:6 (2007), 639–661.
6. [6] Bushe, C, Shaw, M, Peveler, RC, A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 22:2 Suppl. (2008), 46–55.
7. [7] Holt, RI, Peveler, RC, Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf) 74:2 (2011), 141–147.
8. [8] Inder, WJ, Castle, D, Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry 45:10 (2011), 830–837.
9. [9] Gallego, JA, Nielsen, J, De Hert, M, Kane, JM, Correll, CU, Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 11:4 (2012), 527–542.
10. [10] Xiang, YT, Chiu, HF, Ungvari, GS, Quality of life and mental health in Chinese culture. Curr Opin Psychiatry 23:1 (2010), 43–47.
11. [11] Chen, SL, Li, LJ, Psychometric proporties of the SCL-90 (in Chinese). Chin J Nerv Ment Dis, 29, 2003, 327.
12. [12] Jenkinson, C, Layte, R, Development and testing of the UK SF-12 (short form health survey). J Health Serv Res Policy 2:1 (1997), 14–18.
13. [13] Zhang, S, Tian, J, Liu, QL, Zhou, HY, He, FR, Ma, X, Reliability and validity of SF-12 among floating population (in Chinese). Chin J Public Health 27 (2011), 226–227.
14. [14] Kelly, DL, Conley, RR, A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology 31:3 (2006), 340–346.
15. [15] Haddad, PM, Wieck, A, Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64:20 (2004), 2291–2314.
16. [16] WHO Collaborating Centre for Drug Statistic Methodology. Guidelines for ATC index with DDDs. 2002, WHO, Oslo.
17. [17] Chong, MY, Tan, CH, Shinfuku, N, Yang, SY, Sim, K, Fujii, S, et al. Prescribing antipsychotic drugs for inpatients with schizophrenia in Asia: comparison of REAP-2001 and REAP-2004 studies. Asia Pac Psychiatr 2 (2010), 77–84.
18. [18] Peveler, RC, Branford, D, Citrome, L, Fitzgerald, P, Harvey, PW, Holt, RI, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 22:2 Suppl. (2008), 98–103.
19. [19] Byerly, MJ, Marcus, RN, Tran, QV, Eudicone, JM, Whitehead, R, Baker, RA, Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res 107:2–3 (2009), 218–222.
20. [20] Yasui-Furukori, N, Furukori, H, Sugawara, N, Fujii, A, Kaneko, S, Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol 30:5 (2010), 596–599.
21. [21] Xiang, YT, Wang, CY, Si, TM, Lee, EH, He, YL, Ungvari, GS, et al. The low frequency of reported sexual dysfunction in Asian patients with schizophrenia (2001-2009): low occurrence or ignored side effect?. Hum Psychopharmacol 26:4–5 (2011), 352–357.
22. [22] Fitzgerald, P, Dinan, TG, Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol 22:2 Suppl. (2008), 12–19.
23. [23] Correll, CU, From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 25:Suppl. 2 (2010), S12–S21.
24. [24] Kapur, S, Langlois, X, Vinken, P, Megens, AA, De Coster, R, Andrews, JS, The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood–brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 302:3 (2002), 1129–1134.
25. [25] Montejo, AL, Rico-Villademoros, F, Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders. J Sex Marital Ther 34:3 (2008), 227–239.